- Coordinator
- Fondazione Policlinico Universitario Campus Bio Medico, Italy
- Runs
- 1 January 2024 to 31 December 2029
- Status
- Running
- EU funding
- €8.4m
- Total cost
- €8.4m
- Partners
- 20 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137315
What the project is doing
In the project's own words, from its summary on CORDIS.
Knee osteoarthritis (OA) is one of the most common causes of pain and disability, affecting over 500 million people worldwide. The tremendous socio-economic burden caused by OA is expected to further increase due to rising life expectancy and obesity. Current therapeutic approaches are limited to pain management or knee arthroplasty, but no disease-modifying or regenerative treatment is available. ENCANTO will address this major unmet clinical need by clinically introducing a combined ATMP for the biological reconstruction of the degenerated joint facet in patellofemoral OA (PFOA).
This tissue-engineered cartilage (N-TEC), based on autologous nasal chondrocytes and a collagen membrane, was previously successfully used for focal cartilage lesions. The central part of ENCANTO is an international, blinded, multicenter, prospective randomized controlled phase II trial to clinically assess the efficacy of N-TEC for the treatment of PFOA. Patients’ samples will be analyzed to retrospectively identify PFOA molecular endotypes and associated biomarker signatures with the most successful clinical outcome after N-TEC implantation, to predictively select responders to therapy.
To achieve these aims ENCANTO brings together tissue engineers with practice in ATMPs, knee surgery and rehabilitation specialists, research institutes experienced in regulatory affairs, health economics and ATMP development, excellent scientists involved in the assessment of OA endotypes, and patients’ representatives. SMEs from the consortium will develop a road map towards commercial exploitation, including centralized marketing authorization.
After demonstrating efficacy for PFOA, N-TEC will be considered for other forms of OA in different joints. ENCANTO will thus introduce the first disease-modifying therapy for cartilage degeneration, enable mobility and social gain for a large patient group and play a pivotal role in strengthening Europe's position in delivering regenerative medicine solutions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fondazione Policlinico Universitario Campus Bio Medico | Roma | Italy | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Ortopadisches Spital Speising GmbH | Wien | Austria | Participant |
| Universitat Basel | Basel | Switzerland | Associatedpartner |
| Universitatsspital Basel | Basel | Switzerland | Associatedpartner |
| crossklinik AG | Basel | Switzerland | Associatedpartner |
| Evangelisches Waldkrankenhaus Spandau Krankenhausbetriebs Ggmbh | Berlin | Germany | Participant |
| Julius-Maximilians-Universitat Wurzburg | Wuerzburg | Germany | Participant |
| Promove-Biotec GmbH | Nurnberg | Germany | Participant |
| Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat | Wurzburg | Germany | Participant |
| Theracell Proigmenes Viotechnologikes Efarmoges Monoprosopi Anonymi Etaireia | N. Kifisia | Greece | Participant |
| Oulun Yliopisto | Oulu | Finland | Participant |
| Klinicka Bolnica Sveti Duh | Zagreb | Croatia | Participant |
| Videoreha Drustvo S Ogranicenom Odgovornoscu Za Usluge | Zagreb | Croatia | Participant |
| Ospedale Galeazzi SpA | Milano | Italy | Third party |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Academisch Ziekenhuis Maastricht | Maastricht | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
| Szpital Specjalistyczny Im. Stefana Zeromskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Krakowie | Krakow | Poland | Participant |
| Vastra Gotalandsregionen | Vanersborg | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI